FDA's Brand Name Review Pilot Fails To Fly
This article was originally published in RPM Report
Executive Summary
A pilot program for reviewing proposed proprietary names for branded drugs and biologics has been terminated by FDA due to a lack of participation by industry. PhRMA thinks the agency should go a step further and abolish the brand name testing process altogether. Will that fly with FDA?